Cytochrome $b_5$ plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine

Marie Stiborová1 · Radek Indra1 · Eva Frei1 · Kateřina Kopečková2 · Heinz H. Schmeiser3 · Tomáš Eckschlager4 · Vojtěch Adam5 · Zbyněk Heger5 · Volker M. Arlt6 · Václav Martinek1

Received: 8 March 2017/ Accepted: 13 April 2017 / Published online: 4 July 2017 © The Author(s) 2017. This article is an open access publication

Abstract Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome $b_5$ reductase and/or cytochrome $b_5$ in Supersomes™ to oxidize this drug. We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome $b_5$ reductase, to mediate ellipticine oxidation in these enzyme systems. Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. Among ellipticine metabolites, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyllepticine were formed by hepatic microsomes as the major metabolites, while 7-hydroxyllepticine and the ellipticine $N^2$-oxide were the minor ones. Human CYP3A4 in Supersomes™ generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyllepticine. Using the 32P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. These adducts were derived from the reaction of 13-hydroxy- and 12-hydroxyllepticine with deoxyguanosine in DNA. In the presence of NADPH or NADH, cytochrome $b_5$ stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. This heme protein also stimulated the formation of both ellipticine-DNA adducts. The results demonstrate that cytochrome $b_5$ plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome $b_5$ mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADPH:cytochrome $b_5$ reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome $b_5$ can act as an allosteric modifier of the CYP3A4 oxygenase.

Graphical abstract
Keywords DNA · Enzymes · Coenzymes · High pressure liquid chromatography

Introduction

Ellipticine (5,11-dimethyl-6H-pyrrolo[4,3-b]carbazole, see Fig. 1) and its derivatives are efficient anticancer compounds that function through multiple mechanisms participating in cell cycle arrest and initiation of apoptosis (for a summary see [1–8]). The predominant mechanisms of ellipticine’s biological effects were proposed to be intercalation into DNA [1, 6, 9] and the inhibition of topoisomerase II [1, 4, 6–8]. Further, we have shown that this antitumor agent forms covalent DNA adducts after enzymatic activation with cytochromes P450 (CYP) and peroxidases [2, 4, 7, 8, 10–17], suggesting an additional DNA-damaging effect of ellipticine. Of the CYP enzymes investigated, human CYP3A4 is the most active enzyme oxidizing ellipticine to 12-hydroxy- and 13-hydroxyellipticine, reactive metabolites that dissociate to ellipticine-12-ylium and ellipticine-13-ylium and bind to DNA (see Fig. 1) [4, 5, 11, 12]. The CYP3A4 isofrom also forms other ellipticine metabolites, including 9-hydroxyellipticine, which is a detoxification product, as well as 7-hydroxyellipticine and ellipticine N^2-oxide as minor metabolites (Fig. 1) [4, 5, 15, 16].

CYP enzymes, including CYP3A4, are components of the monoxygenase system located in the membrane of the endoplasmic reticulum (microsomes). This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b5 system also contains other enzymes such as NADPH:cytochrome c reductase and NADH might even substitute the POR/NADPH system in the CYP3A4 catalysis of this marker reaction. Recently, we have found that the NADH:cytochrome b5 reductase/cytochrome b5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). This NADH-dependent system can, therefore, function as a sole electron donor for both reduction steps in the reaction cycles of CYP1A1 [39, 40] and CYP3A4 [26, 28]. Here, we investigated in detail, whether the NADH:cytochrome b5 reductase/cytochrome b5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine. Another aim of this work was to shed more light on the further functions of cytochrome b5 in this CYP3A4-mediated reaction.

Results and discussion

Oxidation of ellipticine by human hepatic microsomes and human CYP3A4 expressed in Supersomes™ in the presence of NADPH and NADH

In the last decade, we have studied in detail the CYP-mediated oxidation of ellipticine using the monoxygenase systems of several species founding that up to five oxidized metabolites are formed [3–5, 8, 11, 15–17, 40–42]. Since reactions of CYPs use molecular oxygen, electrons are essential for this process. In addition to the classical
Cytochrome \( b_5 \) plays a dual role in the reaction cycle of cytochrome P450 3A4 during...

reductase POR with its cofactor NADPH, cytochrome \( b_5 \) plus NADH:cytochrome \( b_5 \) reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes™)

Fig. 1 Scheme of ellipticine metabolism by CYPs and peroxidases showing the identified metabolites and those proposed to form DNA adducts. The compounds shown in brackets were not detected under the experimental conditions and/or not structurally characterized. The CYP enzymes predominantly oxidizing ellipticine shown in the figure were identified in this work and/or in previous studies [11, 16]
containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADPH:cytochrome b5 reductase and cytochrome b5, and (iii) the analogous Supersomes™, but also containing over-expressed cytochrome b5, at a molar ratio of CYP3A4 to cytochrome b5 of 1:5. NADPH and NADH, cofactors of the two microsomal reductases POR and NADPH:cytochrome b5 reductase, respectively, were utilized as electron donors for CYP-mediated ellipticine oxidation. The ellipticine metabolite profile formed by the used enzymatic systems was determined by HPLC analysis and ellipticine metabolites were identified by NMR and/or mass spectrometry as described previously [11].

As shown in our previous studies [11, 16], in the presence of NADPH five ellipticine metabolites were formed in human hepatic microsomes. They were structurally characterized previously [11] to be 9-hydroxy-, 12-hydroxy-, 13-hydroxy-, and 7-hydroxyellipticine, in addition to N²-oxide of ellipticine. Here, we show that three of these metabolites are also formed in human hepatic microsomes in the presence of NADH instead of NADPH (Fig. 2). As with NADPH, 9-hydroxyellipticine and 13-hydroxyellipticine were produced as the major metabolic products, while 12-hydroxyellipticine was the minor one. 7-Hydroxyellipticine and ellipticine N²-oxide were not detectable in the presence of NADH (Fig. 2). In the presence of NADH, the amounts of ellipticine metabolites were up to five-times lower than in the presence of NADPH. Negligible amounts or no ellipticine metabolites (7-hydroxyellipticine and ellipticine N²-oxide) were found when NADPH or NADH was omitted from the incubation mixtures containing human hepatic microsomes (Fig. 2).

These results demonstrated that not only NADPH, but also NADH acts as an electron donor for the reduction of CYPs during ellipticine oxidation in human liver microsomes. These results also suggested that NADH can even serve as an exclusive electron donor for CYP in its catalytic cycle independent of NADPH and POR. This suggestion was confirmed by the finding that NADH does not function as a coenzyme of POR when cytochrome c is used as a substrate [39, 40].

To evaluate the suitability of the CYP3A4-Supersomes™ systems [see systems (ii) and (iii)] for our experiments, we first tested whether they are functionally active by testing the CYP3A4 marker activity, testosterone 6-β-hydroxylation. Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b5 stimulated this reaction enormously (Fig. 3). Based on these findings, we could argue that the Supersomal CYP3A4 systems were suitable for our further enzymatic studies, where ellipticine was analyzed to be a CYP3A4 substrate. Our results with these CYP3A4 systems are fully in accordance with the studies by Guengerich and his coworkers [26, 28], where they used human recombinant CYP3A4 reconstituted either with POR plus NADPH or NADH:cytochrome b5 reductase with NADH in the presence of cytochrome b5 in liposomes.

Human recombinant CYP3A4 expressed in the Supersomal enzymatic systems used here oxidized ellipticine only to three metabolites; 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine, again both in the presence of NADPH and NADH (Fig. 4). The formation of 7-hydroxyellipticine and the N²-oxide of ellipticine was too low to be accurately quantified. NADH was less effective than NADPH as electron donor. In control incubations performed without the addition of external NADPH or NADH only low amounts of ellipticine metabolites were detected (Fig. 4).

Next, we utilized system (iii) where cytochrome b5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b5 of 1:5 already in the cells from which CYP3A4-Supersomes™ (microsomes) were isolated. In the presence of NADPH, 4-, 5-, and 3.2-fold increased levels of 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine, respectively, were produced (Fig. 4). These results demonstrated that cytochrome b5 might function as a donor for the second electron transferred by POR from NADPH, which is in line with our earlier studies [15, 16]. In our previous work [15] a different procedure to include cytochrome b5 into Supersomes™ was utilized. Cytochrome b5 was reconstituted in Supersomes™, over-expressing POR with CYP3A4 in vitro (again in a molar ratio of CYP3A4:cytochrome b5 of 1:5). In this system, reconstitution with cytochrome b5 only increased the
Cytochrome \( b_5 \) plays a dual role in the reaction cycle of cytochrome P450 3A4 during...

Formation of ellipticine-derived-DNA adducts by human hepatic microsomes and human CYP3A4 expressed in Supersomes™ in the presence of NADPH and NADH

In further experiments, DNA adduct formation was analyzed in incubations with ellipticine and human hepatic...
Two DNA adducts were detected by the \(^{32}\text{P}\)-postlabeling method \([2, 11–16]\) derived from ellipticine activated with human hepatic microsomes or CYP3A4-Supersomes\(^\text{TM}\) (Fig. 5), both in the presence of NADPH and NADH (Figs. 6, 7). One major adduct (assigned spot 1 in Fig. 5a–d) was previously shown \([11]\) to be generated by the reaction of guanine in DNA with ellipticine-13-ylium which is formed by the decomposition of 13-hydroxyellipticine (Fig. 1). One minor adduct (assigned adduct spot 2 in Fig. 5a–c, e) was previously shown \([12]\) to be generated by reaction of guanine in DNA with ellipticine-12-ylium formed from 12-hydroxyellipticine (Fig. 1). These two adducts were analogous to those formed in several cancer cells in vitro \([43–46]\) and in healthy \([13, 14, 47]\) (Fig. 5c) and tumor tissues in vivo \([4]\).

The levels of ellipticine-derived adduct 1 (formed predominantly by CYP3A4) \([11, 15, 16]\) generated in human microsomes were 2.8-fold lower with NADH than with NADPH as the cofactor (Fig. 6), which is in agreement with a 2.6-fold lower efficiency of ellipticine oxidation to 13-hydroxyellipticine by human microsomes in the presence of NADH (Fig. 2). Control incubations carried out without NADPH or NADH were essentially free of adduct spot 1, but adduct spot 2 was always detected (Fig. 6), indicating that adduct 2 might be also formed by autooxidation as reported previously \([2, 4]\).

With human recombinant CYP3A4 expressed in Supersomes\(^\text{TM}\) the adducts formed were the same as those generated by human hepatic microsomes, both in the presence of NADPH and NADH. But NADH as a coenzyme was again less efficient than NADPH (Fig. 7). When NADPH or NADH was omitted from the incubation mixtures containing CYP3A4-Supersomes\(^\text{TM}\), only low amounts of adduct spot 2 were detected (Fig. 7).

In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes\(^\text{TM}\) with over-expressed cytochrome \(b_5\), shown in Fig. 4, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 7).

**Conclusions**

The present study was aimed to advance our knowledge regarding the role of cytochrome \(b_5\) in the reaction cycle of CYP3A4 catalyzing the oxidation of the anticancer drug ellipticine. Our results demonstrated that the function of cytochrome \(b_5\) in this reaction is complex. We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes\(^\text{TM}\), where the reductases POR and NADH:cytochrome \(b_5\) reductase and cytochrome \(b_5\) are expressed, is enhanced by cytochrome \(b_5\). Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme.
of another microsomal reductase, NADH:cytochrome \( b_5 \) reductase. These findings demonstrated that cytochrome \( b_5 \) is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome \( b_5 \) reductase and cytochrome \( b_5 \), and thus also without any participation of NADPH and POR. Our data confirmed previous results found for CYP3A4 \([26, 28]\) and for CYP1A1 \([39, 40]\) that NADH:cytochrome \( b_5 \) reductase/cytochrome \( b_5 \)/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system \([18, 19]\). This is an important finding, because substitution of the POR/NADPH system by another reductase system might be clinically relevant for compensation or the lack of defect in POR in patients suffering from diseases caused by mutations of the POR gene. For example for patients with Antley-Bixler syndrome (OMIM 201750), a disorder characterized by severe developmental abnormalities and exhibiting considerable numbers of different haplotypes of the POR gene \([48, 49]\). Investigation of this feature is, therefore, a challenge for future studies.

Here, we showed that if NADPH is substituted by NADH, ellipticine oxidation is catalyzed by experimental CYP3A4 enzymatic systems. Such NADH-mediated activity of the employed CYP3A4 systems was proven by the formation of oxidized ellipticine metabolites as well as by the generation of ellipticine-derived DNA adducts, which were the same as in the system where NADPH was used as electron donor.

The results of our present study as well as those reported previously \([15]\) indicated that cytochrome \( b_5 \) can play a dual role in the CYP3A4-mediated oxidation of ellipticine. Specifically, as shown here, (i) it acts as a sole electron donor to CYP3A4 during its reaction cycle and (ii) it can also act as an allosteric modifier of CYP3A4 oxygenase \([15]\). The finding that cytochrome \( b_5 \) with its reductase, NADH:cytochrome \( b_5 \) reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. It will be a challenge to study the kinetics and structural features of this novel phenomenon.

### Experimental

#### Chemicals and CYP3A4 subcellular systems

Ellipticine, NADH (as disodium salt; purity \( \sim 95\% \)), and NADPH (as tetrasodium salt; \( \sim 98\% \) purity) were obtained from Sigma Chemical Co (St Louis, MO, USA). Testosterone and 6-\( \beta \)-hydroxytestosterone were purchased from Merck (Darmstadt, Germany).

#### CYP3A4 subcellular systems

CYP3A4-Supersomes\(^\text{TM}\), microsomes isolated from insect cells transfected with a baculovirus construct containing cDNA of human CYP3A4 and POR that are, therefore, over-expressed in these microsomes, were purchased from the Gentest Corp. (Woburn, MI, USA). However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (i.e. NADH:cytochrome \( b_5 \) reductase and cytochrome \( b_5 \)) are also expressed at basal levels in these Supersomes\(^\text{TM}\) (Gentest Corp., Woburn, MI, USA). We also utilized CYP3A4-Supersomes\(^\text{TM}\) which also contained over-expressed cytochrome \( b_5 \), in a molar ratio of CYP3A4 to cytochrome \( b_5 \) of 1–5 (Gentest Corp., Woburn, MI, USA). Pooled human hepatic microsomes were from Gentest Corp. (Woburn, MI, USA).

#### Incubations to study the metabolism of ellipticine

Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes\(^\text{TM}\) contained in a final volume of 0.5 cm\(^3\) 100 mmol dm\(^{-3}\) potassium phosphate buffer (pH 7.4), 1 mmol dm\(^{-3}\) NADPH or NADH, 0.025 mmol dm\(^{-3}\) ellipticine (dissolved in 0.005 cm\(^3\) dimethyl sulfoxide, DMSO) and...
0.5 mg protein of human hepatic microsomes or 100 nmol dm\textsuperscript{-3} human recombinant CYP3A4 in Supersomes\textsuperscript{TM} either with or without cytochrome \textsubscript{b}S. The same amount of solvent (DMSO) was used in control incubations without ellipticine. With this DMSO concentration (1% final concentration), no inhibition of the NADPH-dependent CYP-catalyzed oxidation of several substrates has been found previously [10, 11, 15–17]. The reaction was initiated by adding the NADPH or NADH. Negative controls lacked either microsomes or Supersomes\textsuperscript{TM} or cofactors or ellipticine. After incubation (37 °C, 20 min), 0.005 cm\textsuperscript{3} 1 mmol dm\textsuperscript{-3} phenacetin in methanol was added as an internal standard; ellipticine metabolism by microsomes has been shown to be linear up to 30 min of incubation [3, 11]. Ellipticine metabolites were extracted twice with ethyl acetate (2 \times 1 cm\textsuperscript{3}), the solvent was evaporated to dryness, residues were dissolved in 0.025 cm\textsuperscript{3} methanol and ellipticine metabolites were separated by HPLC as reported [3, 11, 15–17]. Ellipticine metabolite peaks were analyzed by HPLC by comparison with metabolite standards whose structures were determined previously by NMR and/or mass spectrometry [11, 12].

**Incubations to study 6-\textit{b}-testosterone hydroxylation by CYP3A4 in Supersomes\textsuperscript{TM}**

The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm\textsuperscript{3}: 100 nmol dm\textsuperscript{-3} potassium phosphate buffer (pH 7.4), 50 \textmu mol dm\textsuperscript{-3} testosterone (0.0025 cm\textsuperscript{3} of stock methanol solution per incubation), 1 mmol dm\textsuperscript{-3} NADPH or NADH, and 100 nmol dm\textsuperscript{-3} human recombinant CYP3A4 in Supersomes\textsuperscript{TM} either with or without cytochrome \textsubscript{b}S. The same amount of solvent (methanol) was used in control incubations without testosterone. The reaction was initiated by adding the NADPH or NADH. Negative control reactions lacked either CYP3A4-Supersomes\textsuperscript{TM} systems, cofactors or testosterone. After incubation (for 15 min, at 37 °C in a shaking incubator), 0.005 cm\textsuperscript{3} 1 mmol dm\textsuperscript{-3} phenacetin in methanol was added as an internal standard; testosterone oxidation was linear up to 30 min of incubation (data not shown). The reaction was terminated by the addition of 0.1 cm\textsuperscript{3} of 1 mol dm\textsuperscript{-3} aqueous Na\textsubscript{2}CO\textsubscript{3} containing 2 mol dm\textsuperscript{-3} NaCl. The metabolites were extracted with 2 \times 1 cm\textsuperscript{3} of dichloromethane and the extracts were evaporated to dryness. The residues were dissolved in the mobile phase for HPLC (see below). Testosterone and its metabolite 6-\textit{b}-hydroxysterosterone were separated on Nucleosil (C18) HPLC column (4.6 \times 25 mm, 5 \textmu m, Macherey–Nagel, Germany). The flow rates, mobile phases and detection wavelength were 0.7 cm\textsuperscript{3} per min, 65:35 methanol/H\textsubscript{2}O (v/v), and 254 nm, respectively [50, 51].

**Determination of DNA adduct formation by ellipticine by \textsuperscript{32}P-postlabeling**

Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm\textsuperscript{-3} human recombinant CYP3A4 in Supersomes\textsuperscript{TM} either with or without cytochrome \textsubscript{b}S, 0.1 mmol dm\textsuperscript{-3} ellipticine (dissolved in 0.0075 cm\textsuperscript{3} methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm\textsuperscript{3} as described previously [2, 4, 15, 16]. The reaction was initiated by adding 0.1 mmol dm\textsuperscript{-3} ellipticine and incubations were carried out at 37 °C for 60 min. The ellipticine-derived DNA adduct formation was shown to be linear up to 90 min [2, 11, 15, 16]. Control incubations were carried out either without human hepatic microsomes or CYP3A4 in Supersomes\textsuperscript{TM} without NADPH (or NADH), without DNA, or without ellipticine. After the incubation, DNA was isolated from the residual water phase by standard phenol/chloroform extraction. DNA adduct formation was analysed using the nuclease P1 version of the \textsuperscript{32}P-postlabeling technique [2, 11, 15, 16]. Resolution of the adducts by thin-layer chromatography (TLC) using polyethylenimine-cellulose plates (Macherey and Nagel, Duren, Germany) was carried out as described [2, 11, 15, 16]. DNA adduct levels (RAL relative adduct labeling) were calculated as described [52].

**Statistical analyses**

Statistical analyses were carried out with mean ± standard deviations (from the original data) of at least three parallel experiments with Student’s \textit{t} test (UNISTAT Statistics Software v6, Unistat Ltd., Highgate, London N6 5UQ, UK). All \textit{P} values were two-tailed and considered significant at the 0.05 level.

**Acknowledgements** Supported by GACR (Grant 17-12816S) and Charles University (Grant UNCE 204025/2012). Work at King’s College London was also supported by Cancer Research UK (Grant No. C313/A14329). Wellcome Trust (Grants 101126/Z/13/Z and 101126/B/13/Z) and Natural Environmental Research Council (Grant NE/L006782/1).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Auclair C (1987) Arch Biochem Biophys 259:1
2. Stiborová M, Bieler CA, Wiessler M, Frei E (2001) Biochem Pharmacol 62:1675
3. Stiborová M, Bořek-Dohalská L, Aimová D, Kotrbková V, Kukačková K, Janouchová K, Ruptová M, Ryšálová H, Huděček J, Frei E (2006) Gen Physiol Biophys 25:245
4. Stiborová M, Ruptová M, Frei E (2011) Biochim Biophys Acta 1814:175
5. Stiborová M, Černá V, Moserová M, Mrízová I, Arlt VM, Frei E (2003) Chem Res Toxicol 16:419
6. Kizek R, Adam V, Hrabeta J, Eckschlager T, Frei E (2007) Int J Cancer 120:243
7. Stiborová M, Indra R, Moserová M, Mrízová I, Arlt VM, Frei E, Stiborová M (2011) Biochem Pharmacol 82:669
8. Pandey AV, Flück CE (2013) Pharmacol Ther 138:229
9. Henderson CJ, McLaughlin LA, Scheer N, Stanley LA, Wolf CR (2012) Drug Metab Pharmacokinet 27:663
10. Indra R, Moserová M, Mrízová I, Arlt VM, Frei E (2008) Toxicol Appl Pharmacol 226:318
11. Indra R, Moserová M, Mrízová I, Arlt VM, Frei E (2009) J Endocrinol 187:267
12. Stiborová M, Bořek-Dohalská L, Aimová D, Kotrbková V, Kukačková K, Janouchová K, Ruptová M, Ryšálová H, Huděček J, Frei E (2006) Gen Physiol Biophys 25:245
13. Stiborová M, Ruptová M, Frei E (2011) Biochim Biophys Acta 1814:175
14. Stiborová M, Rupertová M, Aimová D, Rys’lava H, Frei E (2004) Cancer Res 64:8374
15. Stiborová M, Ruptová M, Frei E (2011) Biochim Biophys Acta 1814:175
16. Stiborová M, Bořek-Dohalská L, Aimová D, Kotrbková V, Kukačková K, Janouchová K, Ruptová M, Ryšálová H, Huděček J, Frei E (2006) Gen Physiol Biophys 25:245
17. Stiborová M, Bořek-Dohalská L, Aimová D, Kotrbková V, Kukačková K, Janouchová K, Ruptová M, Ryšálová H, Huděček J, Frei E (2006) Gen Physiol Biophys 25:245